Introduction
T he international breast cancer burden has changed over time. Changing lifestyles and early detection have markedly influenced breast cancer incidence in recent years. 1 Simultaneously, advances in breast cancer therapy and early detection have had a profound effect on breast cancer mortality. This includes the introduction of mammographic screening programmes in many countries. The effect of long-running screening programmes with both high coverage and attendance rates, like the Dutch programme, is becoming increasingly visible. 2, 3 Researchers often refer to age-standardized incidence and mortality rates in studies on the burden of breast cancer. An alternative measure is the lifetime risk, which is calculated by converting the population-based rates into individual risks. The lifetime risk is a summary measure that combines different population characteristics, thereby also allowing for competing risk adjustments. The lifetime risk is often the preferred measure in public health communications, as it is perceived to be both informative and easily comprehensible. In addition, it corresponds to the more individual perspective that is increasingly applied in prevention, including personalized screening. 4 Lifetime risks can be calculated for newborns, which give the probability of a breast cancer diagnosis or breast cancer death throughout an entire lifetime. Furthermore, both short-and long-term risks for women who have been cancerfree up until a certain age can be calculated. The 10-year breast cancer risk for a 50-year-old woman, for example, may be very helpful in the evaluation of the screening starting age.
Cancer registry data covering the whole country since 1989 are available from the Netherlands Cancer Registry (NCR). 5 Because of the high-quality long-running cancer registry, long-term trends in cancer epidemiology can easily be studied in the Netherlands. These data have been used previously to calculate lifetime risks. The mostcited estimate, however, dates from 2003. The average lifetime risk for invasive tumours was estimated to be 1 in 8 (12.7%) at that time, 6 whereas the estimate including in situ tumours was nearly 1% higher (13.6%). 7 In this paper, we illustrate the breast cancer burden in the Netherlands by means of lifetime and age-conditional risks. The aim of this study is to identify changes in absolute risk of primary breast cancer diagnosis and death in the Netherlands over time. We present the risk of invasive tumours alone as well as the combined risk of invasive tumours and ductal carcinomas in situ (DCIS).
Methods

Data source
Data on breast cancer incidence and mortality from 1990 to 2010 were obtained from the NCR. 5 Tumours in this registry are coded according to the International Classification of Diseases for Oncology (ICD-O). Regarding multiple primaries, the registry follows the guidelines developed by the International Agency for Research on Cancer (IARC) and the International Association of Cancer Registries (IACR). We included both DCIS and invasive tumours. The data were divided into 5-year age groups, with the open-ended group of 85 years and older. Information on the size of the female population and all-cause female mortality rates (based on age at 31 December) for the same time period were obtained from Statistics Netherlands. 8 
Statistical analysis
Lifetime and age-conditional risks were calculated for different years using the life-table method. The calculations were based on the observed incidence and mortality rates in the corresponding year. Age-conditional risks refer to the risk of an event in a time window after a certain age, conditional on being cancer free (risk of developing breast cancer) or being alive (risk of dying of breast cancer) up until that age. The underlying assumption of all calculated risks is that the incidence and mortality rates are constant during the time window for which the risk is estimated. The life-table method was first described by Goldberg. 9 In short, agespecific mortality and incidence rates are applied to a hypothetical birth cohort. The risks are based on the number of diagnoses or deaths in this cohort. By including all-cause mortality, risks are adjusted for competing causes of death. This method is incorporated in the DevCan software, which was developed by the National Cancer Institute. 10 The programme provides risks and the corresponding 95% confidence intervals (CI) for every 5-year age group. 11, 12 The population at risk was based on the female midyear population. This was calculated as the average of the female population at 1 January and 31 December of the same year.
Results
In 2010, over 13 000 women were diagnosed with invasive breast cancer in the Netherlands. The associated lifetime risks of developing breast cancer are presented in table 1. The lifetime risk of developing invasive breast cancer was estimated at 13.6% (1 in 7.4 women) in 2010. The absolute risk difference with 1990 and 2000 is 3.1% (10.5%; 1 in 9.5 women) and 1.1% (12.5%; 1 in 8.0 women), respectively. When DCIS tumours are included, the lifetime risk for 2010 becomes 1.7% higher. This results in a combined risk of breast cancer of 15.2% (1 in 6.6 women). The combined risk was 10.8% (1 in 9.3 women) in 1990 and 13.5% (1 in 7.4 women) in 2000.
In addition, table 1 shows the age-conditional risks, including both 10-year risks and remaining lifetime risks. The risk to develop breast cancer by the age of 50 was estimated at 2.6% in 2010. Compared with a total lifetime risk of 15.2% (100 Â 2.6/ 15.2 = 17% of the lifetime risk), this suggests that most women are still being diagnosed after the age of 50.
The risk of being diagnosed with breast cancer, the 10-year risk as well as the remaining lifetime risk, has increased since 1990 for most ages. The exception is the 10-year risk between 70 and 80, which decreased from a combined estimate of 4.0% (1 in 25 women) in 2000 to 3.7% (1 in 27 women) in 2010. The highest risk of breast cancer diagnosis was between 60 and 70 years in 2010 (combined risk of 4.2%). This seems to be an age shift in comparison with previous years, when the highest risk was observed between 70 and 80 (3.1% in 1990 and 4.0% in 2000). A graphical representation of the changes in remaining lifetime risk of breast cancer diagnosis over time can be seen in figure 1 .
In 2010, more than 3000 Dutch women died from breast cancer. The lifetime risk of breast cancer death was 3.8% (1 in 27 women) in 2010, which is lower than in 1990 (4.5%; 1 in 22 women) and 2000 (4.2%; 1 in 24 women) (table 2). Most breast cancer deaths were estimated to occur at older age (1990: 100% Â (4.5À2.2)/4.5 = 52% of the lifetime risk after 70 years; 2000: 100% Â (4.2À1.8)/4.2 = 57%; 2010: 100% Â (3.8À1.5)/3.8 = 61%). One of the strengths of this study is the inclusion of DCIS diagnoses. DCIS is a pre-invasive lesion that is treated as breast cancer and, therefore, contributes to the overall perceived burden of the disease in society. The inclusion of these tumours also resulted in a limitation. The risk calculations were based on first diagnosis of breast cancer. A second tumour could, however, still be included when the second tumour has a different behaviour code or is in a different histological subgroup. The risk of being diagnosed with second breast cancer after being diagnosed with breast carcinoma in situ is increased. 13 Therefore, the breast cancer risk is slightly overestimated. Another limitation of this study is that we assumed constant rates of incidence and mortality, although especially the mortality rates are known to change within a lifetime. This should be taken into account when interpreting the lifetime risks. While one may thus be intuitively inclined to estimate case-fatality rate by dividing risk of diagnosis by risk of death, this does not necessarily give a realistic estimate due to the potential changes in rates. In that sense, similar considerations apply to this estimate and the mortality to incidence (M/I) ratio.
14 Breast cancer survival would be estimated at 75% using the results from our study, which is lower than the estimated 5-year survival for patients diagnosed in 2006-2010 (86%). 5 The increasing breast cancer risk is in line with results from previous studies on breast cancer incidence and risk.
2,3,6,7,15,16 As described in the introduction, the risk of invasive breast cancer was estimated at 12.7% between 1999 and 2003, 6 whereas the combined risk of in situ and invasive tumours was 13.6% in 2003. 7 The latter study, however, included all in situ tumours even though only DCIS is treated as breast cancer. The rising Dutch breast cancer incidence from 1975 onward appeared to be strongly correlated with the implementation of the breast cancer screening programme for women aged 50-74 years. 2, 16 The incidence still appeared to be increasing, however, after the programme had entered a steady state and participation rates stabilized. The differences in risks between 2000 and 2010 suggest that the breast cancer incidence has continued to increase over the last years. The breast cancer risk increased mostly in the younger age groups, whereas the 10-year risk between 70 and 80 years slightly decreased. This can be explained by the detection of tumours at an earlier age due to screening, also referred to as the lead time effect. As was shown in table 1, the risk of DCIS appears to have increased more than the risk of invasive tumours, which may be associated with breast cancer screening.
The rise in the combined breast cancer risk could have different explanations. Firstly, this may be attributed to ageing of the population, although the risk increase in every age group suggests that it is not the only explanation. A second explanation could be overdiagnosis. Overdiagnosis means that women are diagnosed with breast cancer through screening who in the absence of screening would not have been diagnosed during their lifetime. Based on the low estimates for overdiagnosis and the stable DCIS distribution in the Netherlands, however, other factors are still expected to have played a role as well. [17] [18] [19] The decreasing physical activity, increasing number of overweight women, and changing dietary patterns may have all contributed. [20] [21] [22] [23] Changes in reproductive patterns (e.g. age at first birth) are also known to have an effect on breast cancer risk. 24 The question whether these changes over time in the Netherlands were large enough to have a significant effect on current breast cancer incidence remains to be elucidated.
The drop in breast cancer mortality risk, on the other hand, could be attributed both to screening and advances in breast cancer treatment, like the increased use of adjuvant therapy. The large mortality decrease in the population that is screened or has been screened is expected to reflect the synergistic effects of treatment and breast cancer screening. After all, early detection will only decrease breast cancer mortality when it is followed by effective treatment. Simultaneously, cancer treatment is most effective and least aggressive when the tumour was detected at an early stage. Table 3 shows a selection of breast cancer risk estimates from different countries. All these estimates were based on the life-table method. International comparisons of risks are difficult, as cancer registries may have a different coverage and use different definitions. In addition, many national reports present the cumulative risk. Because the cumulative risk is not adjusted for competing causes of death, it may overestimate the breast cancer risk in the population. 25 The Dutch breast cancer incidence is known to be relatively high in international comparisons. 26 In several highincome countries, stabilization or even a decline in breast cancer incidence has been observed over the past decade.
1 This is often attributed to a decreased use of post-menopausal hormone therapy (HT). 27, 28 In the Netherlands, baseline use of HT was relatively low and a decline of breast cancer risk due to changes in HT-use was thus not apparent. 29, 30 The Dutch breast cancer mortality is high as well compared with other countries, but this is mainly driven by the high incidence because survival has been improving. 31 It has become clear that the breast cancer burden is still changing, and this may have a large impact on society. With both population size and proportion of older adults increasing, especially when the baby-boom generation starts ageing, the absolute number of breast cancer cases is only expected to rise. An increasing number of patients and a decreasing risk of death suggest that there will be more breast cancer survivors. They will have to receive aftercare and followup. Although the risk of relapse is actually decreasing, 36 the aftercare could still be extensive due to the severe side effects associated with systemic treatment. Chemotherapy is known to affect the cardiovascular system, for example, thereby inducing cardiovascular disease. 37 This is especially problematic considering the number of women with pre-existing cardiovascular disease in this age group. Even with decreasing mortality, the burden thus remains considerable. As was reported in a study on the effect of ageing on cancer burden in the USA, the combination of ageing and the growing costs of individual cancer care necessitates careful planning of health care and allocation of resources. 38, 39 A major focus should be innovation of preventive measures. Lifestyle changes are expected to have a pivotal role in decreasing breast cancer risk, although interventions such as preventive therapy are also being explored. Tamoxifen and raloxifene have both been approved as preventive therapy by the US Food and Drug Administration, whereas other agents (e.g. aromatase inhibitors) are still being studied. 40 Secondary prevention, such as breast cancer screening, may not lower the number of breast cancer cases, but it may further decrease the number of deaths and result in the use of less aggressive treatment with fewer side effects. In general, risk-based preventive methods, where the preventive strategy is adapted based on baseline risk, are increasingly advocated. 4 Stratification of the lifetime risks on other risk factors could be used for identification of risk groups and the implementation of differential preventive strategies. This may help create a favourable benefit-risk ratio for both low-and high-risk groups.
In conclusion, the risk of breast cancer death has decreased, but the burden of the disease is still significant. Breast cancer screening and breast cancer therapy are both developing at a quick pace, which may further decrease breast cancer mortality. Preventive measures will have to put a halt to the growing risk of developing breast cancer and the side effects of cancer treatment. In order to keep breast cancer management and prevention up-to-date, it remains important to closely monitor the ever-changing breast cancer burden.
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Key points
Current estimates on breast cancer risk are needed to assess the extent to which breast cancer burden has kept changing after the implementation of screening programmes. Breast cancer risk has continued to increase over the years, long after the introduction of breast cancer screening in the Netherlands. Breast cancer mortality, on the other hand, has clearly decreased over time. Overall, the burden of breast cancer is still significant. With changing lifestyles and demographics, especially ageing of the population, timely monitoring of breast cancer burden is essential in planning breast cancer management. a: All estimates were obtained using the life-table method. The UK estimate was adjusted for multiple primaries. 25, 34 b: Estimate based on current study.
